To establish a suitable model for our study, we first characterized a pair of MYC-amplified therapy-naive CHLA-15 and drug-resistant CHLA-20 neuroblastoma cell lines derived from tumors of the same patient at diagnosis and at relapse after multimodal therapy, respectively [22]. The gene discussed is MYC; the disease is neuroblastoma.